Metastatic melanoma: chemotherapy to biochemotherapy (Q34573040)

3 August 2017

1 reference

title

Metastatic melanoma: chemotherapy to biochemotherapy (English)

1 reference

3 August 2017

1 reference

1 reference

Steven J O'Day

1

1 reference

3 August 2017

Christina J Kim

series ordinal

2

1 reference

3 August 2017

Douglas S Reintgen

series ordinal

3

1 reference

3 August 2017

publication date

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

9

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

31-38

1 reference

3 August 2017

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Cutaneous melanoma: prognosis and treatment results worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Histamine: a novel approach to cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900105

10.1177/107327480200900105

21 January 2018

Identifiers

DOI

0 references

1 reference